Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesTen mg dexrabeprazole daily is as effective as 20 mg dexrabeprazole daily
World Journal of Gastroenterology, 08/08/08
Kanakia R et al. - This report shows that the efficacy of 10 mg dexrabeprazole daily is equivalent to that of 20 mg dexrabeprazole daily against GERD. This implies that a dose of 10 mg dexrabeprazole is sufficient to block the maximum amount of proton pumps without any need to double the dose as suggested with rabeprazole.
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
Annals of Oncology, 12/04/09
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors
Annals of Oncology, 12/04/09
Sponsor
Article Search
Sponsor